According to The Fly, in a latest note to investors, a research analyst has provided a rating update for the IntelGenx Technologies (IGX). The company recieved Buy rating from H.C. Wainwright’s analyst Swayampakula Ramakanth.
According to TipRanks.com, Ramakanth is a 3-star analyst with an average return of 2.2% and a 35.5% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Diffusion Pharmaceuticals Inc, IntelGenx Technologies, and Trillium Therapeutics.
Read also: Why OncoSec Medical (ONCS) Stock Crashed Today
The the analyst consensus on IntelGenx Technologies is currently a Moderate Buy rating.
IntelGenx Technologies’ market cap is currently C$55.73M and has a P/E ratio of 0. The company has a Price to Book ratio of 25.30.
IntelGenx Technologies Corp. engages in the development of novel oral immediate-release and controlled-release products for the pharmaceutical market. Its products include rizaport, tadalafil, loxapine, and montelukast.
The company’s shares closed on Friday at C$0.79, close to its 52-week low of C$0.77.
